The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2008Effects of noradrenergic or serotoninergic system lesions combined with NS lesions on rodent models of 'non-motor'-like symptoms
Objective/Rationale:
Parkinson’s disease is widely attributed to neuropathy of dopaminergic neurones in the nigrostriatal (NS) pathway. Degeneration of noradrenergic and serotonergic neurones in the... -
Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008Neuroimaging Markers Predict Cognitive Decline in PD
Objective/Rationale:
Isolated cognitive impairments are common in PD; they increase in number and severity with advancing age and motor disability but their relation to the risk of developing dementia... -
Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008Validation of the Dopamine-depleted CHT Hemizygous Pre-Clinical Model as an Animal Model of Parkinson's Disease with Dementia
Objective/Rationale:
Parkinson’s disease is traditionally thought of as a motor disorder. However, in addition to problems with movements, patients frequently develop cognitive problems leading to... -
Cognitive Deficits and Mood Disorders in Parkinson's Disease, 2008Validating the Montreal Cognitive Assessment for the Diagnosis of Mild Cognitive Impairment in Parkinson's Disease
Objective/Rationale:
Dementia affects up to 80 percent of Parkinson’s disease patients, and the prevalence of other dementias including Alzheimer’s disease is high in this age group. A need exists for... -
Rapid Response Innovation Awards, 2007Neuroprotective effects of isradipine in a pre-clinical model of Parkinson’s disease
Objective/Rationale:
Recent work by our group has shown that blocking L-type Ca2+ channels protects vulnerable dopaminergic neurons in three animal models Parkinson’s disease (PD). Isradipine, a high... -
Rapid Response Innovation Awards, 2007Genetic characterization of Omi/Htra2 (PARK13) in autosomal dominant and sporadic Parkinson’s disease
Objective/Rationale:
Identification of DNA variations that cause familial/sporadic parkinsonism has provided insight into the biological pathways involved in disease. Thirteen loci (PARK1-13) have...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.